Our Team

We have an established lab and leadership team, in addition to our scientific, clinical, and regulatory advisors.



Genine Winslow, MSc

Founder, CEO & Board President
Gene Therapy Product Development

Genine founded Chameleon Biosciences in 2017 to provide next-generation gene therapies to treat more patients with rare genetic diseases.

Prior to founding Chameleon, Ms. Winslow was the Director of Analytics at Audentes Therapeutics which focused on developing gene therapies for Myotubular Myopathy, Pompe Disease, and CASQ2-related Catecholaminergic Polymorphic ventricular tachycardia (CPVT). At BioMarin, she was a Lead Scientist playing a key role in testing and process development for a Hemophilia A gene therapy product. Before moving to BioMarin, Ms. Winslow was instrumental in developing the testing, characterization and process development of Lentiviral-based gene therapies for Cerebral Adrenoleukodystrophy, Sickle Cell Anemia and Beta Thalassemia as a scientist at BlueBird Bio. Ms. Winslow began her gene therapy career while at Cell Genesys by contributing to early CAR-T programs.

All of the gene therapy programs that Ms. Winslow was involved with are in clinical trials, 4 in late-stage or pivotal clinical trials, and one on the market. Ms. Winslow graduated from UC Davis with a B.Sc. in Genetics and from UC Berkeley with a M.Sc. in Molecular and Cell Biology with emphasis in Immunology.


Casey Maguire, PhD

Co-Founder & Advisor
Assistant Professor Neurology, Harvard University

Casey has over 17 years of experience in genetic engineering of virus vectors for gene therapy applications. His research has been devoted to building better virus-based gene delivery systems to overcome in vivo obstacles to efficient gene therapy. He discovered and continues to develop exo-AAV, a novel gene therapy platform with several publications describing promising results in preclinical models of human disease.

Dr. Maguire authored key IP that is foundational to Chameleon Biosciences; has authored two issued patents and numerous other patent applications that are pending. Dr. Maguire has authored 38 peer reviewed journal articles and review articles and has served on the editorial board for Nature publishing group.

He obtained his PhD in Microbiology and Immunology from the University of Rochester School of Medicine and Dentistry (2006) and did a postdoctoral fellowship at the Massachusetts General Hospital (MGH). He is currently an Assistant Professor of Neurology at Harvard Medical School and a Principal Investigator at the MGH.


Jeffery S. Vick, MBA


Jeff brings more than 25 years of senior management experience in the business and legal side of the Biopharmaceutical Industry in both the USA and Europe. He has particular expertise in Gene Therapy, having built the business development and Intellectual Property group at Genethon from 2012 – 2106, served as VP Business Development and IP at the GenCell division of Aventis from 2002 – 2006 and negotiated and signed many collaborations in the area including those which formed the founding products for both Audentes and GenSight.

Mr. Vick has worked as a venture capitalist, founded, grown and sold multiple companies, and served as CEO of the publicly traded company Silence Therapeutics from 2007– 2008. In 1992 he joined the senior management team of the seed stage start- up company DepoTech Corporation (now the publicly traded company Pacira) as head of Business Development, Intellectual Property and Market Research. He and his colleagues grew the company from 5 to 300 people, brought an oncology product from preclinical stage through registration, built and certified a GMP manufacturing facility to support product launch, signed multiple collaborations, and took the company public prior to leaving in 1997 to join Sanderling Venture Capital. Pacira now has 3 products on the market started during his tenure.

He earned an MBA from Stanford University, an MS Chemistry from UC San Diego and a BS Chemistry from the University of Virginia. Jeff has lived in Europe since 2000.


Monica Miller, MS, EdD

Senior Vice President,
Program Development and Operations
Rare Disease Programs

Monica has 20 years of scientific management and drug development experience in a range of therapeutic areas including gene therapy, immuno-oncology and rare diseases. With experiences from Sangamo Therapeutics, Lawrence Berkeley National Labs, BioMarin, Audentes and Xencor, Dr. Miller has a track record of success in alliance governance, operations, program management, and leadership of cross-functional and executive level teams.

She holds a doctorate in Organizational Leadership from Pepperdine University, where her thesis compared key leadership attributes, skills and challenges between patient advocates in biopharma and non-profit organizations. Dr, Miller also has an MS (Animal Science, emphasis in Reproductive Physiology) from the University of Arizona, and BS (Animal Science) from the University of Minnesota.

Paul Fitzpatrick

Paul Fitzpatrick, PhD

Vice President,
Research and Development

Paul has more than 20 years of biotech leadership experience in growing teams and advancing innovative therapies. Most recently, Paul has been at Zogenix, with a focus on bioprocessing and CMC execution strategies. Prior to Zogenix, Paul had an impactful 20-year career at BioMarin, where he led the Biologics and Production Group, including scientific and operational responsibility for research stage biologics and AAV production, as well as early stage process analytics and structural, cellular, and protein biology fundamental research.

Paul earned a Ph.D. in applied biochemistry from the Massachusetts Institute of Technology and Bachelor of Science degrees in both biology and chemistry from UC Irvine.

Alan Belicha, PhD

Alan Belicha

Vice President,
Business Development

Alan has 10 years of experience in life sciences business development harnessing investor relationship and undertaking end-to-end assessments and valuations of life science innovations. With deep expertise in immune oncology, viral diseases, and gene therapy, Alan’s ability to quickly adapt in dynamic situations has led to many successes at the negotiating table where he has negotiated agreements valued at over $1.3 billion dollars.

Alan earned a BS in Biotechnology and Clinical Laboratory Sciences from the University of Buffalo then, while at Roswell Park Comprehensive Cancer Center, Alan focused on tumor immunology earning a Ph.D. in Molecular Tumor Immunology. He did his post doc work at Icahn School of Medicine at Mount Sinai School of Medicine in New York City where he studied the reverse genetics of influenza A viruses.



Thomas Chalberg, PhD

Board Director / Independent
Entrepreneur, Executive, Investor
Polymerase Capital

Ran Geng

Board Director / Matrix Partners Representative
Healthcare VC

Winnie Wan,

Board Director / Executive Advisor
Miller Center for Social Entrepreneurship,
Santa Clara University


Suyash Prasad, MD

Executive Clinical Advisor
Royal College of Physicians;
Chief Medical Officer, VP of Research & Development,
Taysha Gene Therapies

Mary Newman, PhD

Executive Advisor - Regulatory Affairs
Chief Development Officer, Taysha Gene Therapies


Elizabeth Berry-Kravis, MD, PhD

Professor of Neurology with Special Qualifications in Child Neurology & Pediatrics Rush University

Raphael Clynes, MD, PhD

Vice President Translational Biology Xencor

Michio Hirano, MD

Professor of Neurology, Chief of Division of Neuromuscular Disorders, Director of H. Houston Merritt Clinical Research Center, Columbia University

Mark Kay, MD, PhD

Dennis Farrey Family Professor in Pediatrics and Professor of Genetics, Stanford University Medical School

David W. Scott, PhD

Professor of Medicine, Vice Chair for Research Uniformed Services University, Health Sciences